Publications by authors named "Yana Gercke"
Article Synopsis
- A study examined the HDL proteome of 16 patients experiencing post-COVID-19 symptoms, including those with post-acute sequelae (PCS) and post-vaccination syndrome (PVS), who were treated with statins and ARBs for 6 weeks.
- Results showed that patients with PCS and PVS had no significant differences in their HDL proteins compared to each other, but both groups exhibited significant alterations in proteins related to metabolism and cell structure when compared to healthy controls.
- Treatment with statins and ARBs improved clinical symptoms and led to changes in the HDL proteome that reduced inflammation in human endothelial cells, indicating that HDL analysis could reveal insights into the disease mechanisms of post-COVID-19 conditions.
Purpose: Multimorbidity and subsequent polypharmacy are highly prevalent in older people. To improve inappropriate drug treatment, listing approaches such as the Beers or FORTA lists have been developed. Latter is the only clinically validated drug list issuing both positive (FORTA labels A, B) and negative (FORTA labels C, D) recommendations.
View Article and Find Full Text PDFBackground/objectives: Polypharmacy and multimorbidity is a threat to older people; hence, listing approaches should support physicians to optimize medication. The FORTA (Fit fOR The Aged) classification of drug appropriateness for older people provides positive or negative labels: A (A-bsolutely), B (B-eneficial), C (C-areful), and D (D-on't). Based on these categories, FORTA-labeled drug lists were developed in 7 European countries or regions; the same approach was used to develop a U.
View Article and Find Full Text PDF